Advances in therapeutic targets-related study on systemic lupus erythematosus.
10.11817/j.issn.1672-7347.2021.200056
- Author:
Xin WANG
1
,
2
,
3
;
Qing ZHANG
1
,
2
,
4
;
Shuaihantian LUO
1
,
2
,
4
;
Huilin ZHANG
5
;
Qianjin LU
1
,
2
,
4
;
Hai LONG
1
,
2
,
6
Author Information
1. Department of Dermatology, Second Xiangya Hospital, Central South University
2. Hunan Key Laboratory of Medical Epigenomics
3. Hunan Clinical Medical Research Center of Major Skin Diseases and Skin Health, Changsha 410011. 178211068@csu.edu.cn.
4. Hunan Clinical Medical Research Center of Major Skin Diseases and Skin Health, Changsha 410011.
5. Department of Nursing, Second Xiangya Hospital, Central South University, Changsha 410011.
6. Hunan Clinical Medical Research Center of Major Skin Diseases and Skin Health, Changsha 410011. dr.hailong@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
IgE autoantibody;
cytokines;
gut microbiota;
systemic lupus erythematosus;
therapeutic targets
- MeSH:
Antibodies, Monoclonal/therapeutic use*;
B-Lymphocytes;
Graft vs Host Disease;
Humans;
Immunosuppressive Agents;
Lupus Erythematosus, Systemic/drug therapy*
- From:
Journal of Central South University(Medical Sciences)
2021;46(11):1267-1275
- CountryChina
- Language:English
-
Abstract:
Systemic lupus erythematosus (SLE) is a chronic and autoimmunity-mediated diffuse connective tissue disease. The mainstay of treatments for SLE mainly relies on corticosteroids and immunosuppressants, which have a series of unavoidable side effects. Therefore, it is of fundamental importance to search novel therapeutic targets for better treatment with favorable efficacy and minor side effects. Recent studies shed light on potential therapeutic targets for SLE, mainly covering the followings: B-cell/plasmocyte-related targets [B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), CD20, CD22, CD19/FcγRIIb, Bruton tyrosine kinase (Btk), and proteasome], T cell-related targets [calcineurin, mammalian target of rapamycin (mTOR), regulatory factor X1 (RFX1), and Rho kinase], macrophage-related targets (macrophage migration inhibitory factor), intracellular signaling molecules, cytokines (cereblon, histone deacetylase 6, Janus activated kinase/signal transducer and activator of transcription), co-stimulating factors (CD28/B7, CD40/CD154), IgE autoantibody, and gut microbiome. Among them, belimumab (a humanized monoclonal antibody against B-lymphocyte stimulator) and telitacicept (a recombinant human B-lymphocyte stimulator receptor-antibody fusion protein) have been sequentially approved for the clinical treatment of SLE in China. A variety of new targeted-therapy drugs are in the Phase 2 or Phase 3 clinical trials,among which anifrolumab (a human monoclonal antibody against type I interferon receptor subunit 1) has completed a Phase 3 clinical trial with good responses achieved, although its incidence of herpes zoster is higher than that in the control group. The research progress in both molecular mechanisms and new drug development for different therapeutic targets have greatly promoted our better and in-depth understanding of the pathogenesis of SLE, and have also reflected the complexity and heterogeneity of the disease. Successful development and clinical application of more novel therapies would no doubt usher in a new era of individualized treatment for SLE in the future.
